Wikisage, the free encyclopedia of the second generation, is digital heritage

Daniel Peterson

From Wikisage
Jump to navigation Jump to search

Daniel Peterson is an American physician in private practice in the state of Nevada, and has been described as a "pioneer" in the treatment of chronic fatigue syndrome (CFS).[1][2] He graduated from the University of Rochester School of Medicine, Rochester, New York, in 1976 and was an intern and resident at the University of Utah Medical Center from 1976-1979. In 1979 he became a diplomat of the American Board of Internal Medicine.[3] He is president of Sierra Internal Medicine of Incline Village, established in 1981.[4]

Work in chronic fatigue syndrome

Peterson with Paul Cheney, was a treating physician at Incline Village during an outbreak of chronic fatigue syndrome that began in 1984 in the Lake Tahoe region.[5] From 1984-87, the illness was recorded in 259 patients in the area by the two physicians. The Lake Tahoe outbreak became the subject of several studies by Peterson and others. In 1995 Peterson and other investigators started conducting a 10 year follow up study on patients seen during the outbreak. The study results were published in 2001 by the Journal of Chronic Fatigue Syndrome.[6] In the 2000 CFS documentary I Remember Me, Peterson was interviewed about his some of his experiences during the Lake Tahoe outbreak.[7]

In 1988, Peterson was the first physician to treat an extremely ill person diagnosed with CFS with the experimental drug Ampligen by obtaining compassionate use permission from the U.S. Food and Drug Administration. Quantitative improvement in the first patient enabled the next pilot study of Ampligen in CFS patients by Peterson and other researchers. During the 1990 CFIDS Conference in Charlotte, North Carolina, Peterson described positive results in 15 CFS patents after he treated them with Ampligen for approximately 6 months.[1] In 1990 and 1991 Peterson was one of four principal investigators for the FDA approved phase II randomized placebo controlled double blind study of the experimental intravenous drug Ampligen. The drug was administered in his Incline Village facility and three other sites.[8] Peterson and others reported there was statistically significant improvement in the patients receiving Ampligen.[9] He is a principal investigator of the FDA-approved open label safety and efficacy phase III drug study of Ampligen for treatment of chronic fatigue syndrome.[10] According to the drug developer Hemispherx Biopharma, a New Drug Application for Ampligen treatment of chronic fatigue syndrome has been filed with the FDA but has not yet been approved.[11][12]

Peterson was a member of the International Chronic Fatigue Syndrome Study Group that coauthored the most widely used clinical and research description of CFS,[13] called the 1994 CDC definition, and the Fukuda definition.[14] He is a coauthor of the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols initiated by Health Canada and published by an international group of researchers in 2003.[15][16][17]

Affiliations

Peterson was part of the founding board, and is a past president of the International Association for CFS/ME,[3] a professional organization advocating for the interests of CFS researchers and clinicians worldwide.[18][19] He is the medical director of the Whittemore Peterson Institute for Neuro-Immune Disease.[3] He is a member of the board of directors and the scientific advisory board of the HHV-6 Foundation,[2] a nonprofit organization promoting human herpesvirus 6 (HHV-6) associated scientific and clinical research.[20]

In 2003 he received the distinguished CFS/FM scientist, physician or healthcare worker Rudy Perpich award, and in 2007 received the Nelson Gantz Outstanding Clinician Award from the International Association for CFS/ME.[21]

In 1999 Peterson was commended by the Assembly and Senate of the State of Nevada, for his work and dedication to persons with chronic fatigue syndrome.[22]

Selected publications

References

References

References:
  1. ↑ 1.0 1.1 Verrillo EF, Gellman LM (1998), "Chronic Fatigue Syndrome: A reatment Guide", Macmillan, 152p, ISBN=0312180667, 20090606 Cite error: Invalid <ref> tag; name "Patient Zero" defined multiple times with different content
  2. ↑ 2.0 2.1 (2004), "HHV-6 Foundation Board of Directors", HHV-6 Foundation, 20090318
  3. ↑ 3.0 3.1 3.2 (2008), "Executive staff", The Whittemore Peterson Institute, 20090111
  4. ↑ (2008), "Sierra Internal Medicine", Dun and Bradstreet, 20090112
  5. ↑ Template:Cite video
  6. ↑ Paula S. Strickland, PhD, MPH; Paul H. Levine, MD; Daniel L. Peterson, MD; Karen O'Brien, BS; Thomas Fears, PhD (2001). "Neuromyasthenia and Chronic Fatigue Syndrome (CFS) in Northern Nevada/California: A Ten-Year Follow-Up of an Outbreak". Journal of Chronic Fatigue Syndrome 9 3/4: 3–14. http://dceg.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?page=abstract&ID=6563&project=dceg. 
  7. ↑ Ebert, Roger (December 7, 2001). "I remember Me" (HTML). Movie Review. Roger Ebert Chicago Suntimes. http://rogerebert.suntimes.com/apps/pbcs.dll/article?AID=/20011207/REVIEWS/112070301/1023. Retrieved 2009-01-07. 
  8. ↑ Johnson, Hillary (1996). Osler's web: inside the labyrinth of the chronic fatigue syndrome epidemic. New York: Crown Publishers. p. 385. ISBN 0-517-70353-X. 
  9. ↑ Strayer DR, Carter WA, Brodsky I, et al (January 1994). "A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome". Clin. Infect. Dis. 18 Suppl 1: S88–95. PMID 8148460. 
  10. ↑ "Study of Ampligen in Chronic Fatigue Syndrome" (HTML). U.S. National Institutes of Health. September 2005. http://clinicaltrials.gov/ct2/show/NCT00215813. Retrieved 2009-01-06. 
  11. ↑ "Business Description: HEM Research, Inc." 1986. Retrieved on February 25, 2007.
  12. ↑ "Ampligen" (htm). Hemispherx Biopharma. http://www.hemispherx.net/content/rnd/drug_candidates.htm. Retrieved 2008-04-26. 
  13. ↑ Wyller VB (2007). "The chronic fatigue syndrome--an update". Acta neurologica Scandinavica. Supplementum 187: 7-14. doi:10.1111/j.1600-0404.2007.00840.x. PMID 17419822. 
  14. ↑ Fukuda K, Straus S, Hickie I, Sharpe M, Dobbins J, Komaroff A (1994). "The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group.". Ann Intern Med 121 (12): 953-9. PMID 7978722. http://www.annals.org/cgi/content/full/121/12/953. 
  15. ↑ Carruthers BM, et al. (2003). "Myalgic encephalomyalitis/chronic fatigue syndrome: Clinical working definition, diagnostic and treatment protocols" (PDF). Journal of Chronic Fatigue Syndrome 11 (1): 7–36. doi:10.1300/J092v11n01_02. http://www.cfids-cab.org/MESA/ccpccd.pdf. 
  16. ↑ Carruthers BM (February 2007). "Definitions and aetiology of myalgic encephalomyelitis: how the Canadian consensus clinical definition of myalgic encephalomyelitis works". J. Clin. Pathol. 60 (2): 117–9. doi:10.1136/jcp.2006.042754. PMID 16935963. 
  17. ↑ Practical General Practice: Guidelines for Effective Clinical Management (5th New edition). Elsevier Health Sciences. 24 April 2006. pp. 419-421. ISBN 9780750688673, 075068867X. 
  18. ↑ Friedberg F, Sohl S, Schmeizer B (2007), "Publication trends in chronic fatigue syndrome: comparisons with fibromyalgia and fatigue: 1995-2004", J Psychosom Res, Aug;63(2):143–6, pmid=17662750
  19. ↑ David Tuller (2008), "Expert Q&A, Learning Firsthand about Chronic Fatigue Syndrome" Interview with Leonard Jason, Apr 30, 20090608
  20. ↑ "HHV-6 Foundation", National Institute of Neurological Disorders and Stroke, 20090215
  21. ↑ "Former IACFS/ME awardees", International Association for CFS/ME, 20090107
  22. ↑ (1999), "AJR14", Nevada Legislative Counsel Bureau, Apr 8, 20090217
Retrieved from "https://en.wikisage.org/w/index.php?title=Daniel_Peterson&oldid=633"